Historical aspects of botulinum toxin used clinically: Part I: is that the right serotype?

This is the authors' abstract. We don't add key points for this paper.

The basis of botulinum toxin use as a neuromedicine started over 40 years ago when the first serotype was chosen for key initial studies in monkeys by Alan Scott and colleagues in the USA. From that point on, the protein has been used extensively and worldwide for treatment of many clinical conditions. But much remains to be documented about the earliest times, the very beginning years when critical choices and decisions were made. This first article in a series looks at the choice of the first botulinum toxin serotype used and why that choice was made.